Compare Crispr Therapeutics AG (CRSP) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fox Corp Class A — how do they compare? Crispr Therapeutics AG trades at $53.92 (market cap $5.23B), while Fox Corp Class A trades at $62.57 (market cap $24.58B). The key difference: Fox Corp Class A is far larger — about 4.7× Crispr Therapeutics AG's market cap, and Fox Corp Class A pays a 0.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | FOXA | |
|---|---|---|
Market Cap | $5.23B | $24.58B |
Sector | Health | Media |
52-Week High | $76.78 | $76.11 |
52-Week Low | $44.34 | $48.79 |
Enterprise Value | $3.65B | $27.94B |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
FOXA trades at $62.30, down 1.77% on the day, with a bullish technical signal and strong quarterly earnings beats. Recent Q2 2026 EPS of $1.79 exceeded the $1.44 estimate, driven by World Cup advertising and Tubi streaming growth. The stock shows robust fundamentals with a P/E of 16.18 and net income margin of 9.84%, supported by $3.32B in operating cash flow for 2025.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, though risks include reliance on sports rights and projected 2026 net cash flow decline. Upside hinges on sustained ad demand and digital segment execution amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
